Hosted on MSN3mon
Precision medicine treatment delivers strong results for infantile fibrosarcoma and other solid tumors
It is poised to redefine the approach to treatment for newly diagnosed fibrosarcoma and other solid tumors with the NTRK gene fusion, potentially reducing or eliminating the need for these ...
The Scientist6mon
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
TSO Comprehensive is FDA approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions that may benefit ...
pharmaphorum9mon
FDA widens label for BMS’ cancer drug Augtyro
BMS claims to have scored again with the latest indication, as Augtyro becomes the only FDA-approved treatment option for NTRK-positive solid tumours with supporting data in patients who have and ...
DelveInsight Business Research, LLP: ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
pharmaphorum6y
Bayer takes control of Loxo duo as Lilly closes takeover
Vitrakvi was approved by the FDA last November for patients with advanced solid tumours with an NTRK gene fusion, and filings in Europe and other markets are in play. Follow-up LOXO-195 – now re ...